Business
Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer
LEXINGTON, Mass., May 15, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the publication of Phase 1b data evaluating botensilimab (BOT), an Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, in patients with treatment-refractory hepatocellular carcinoma (HCC) who had progressed following prior immunotherapy. The manuscript, titled "A phase 1b study of botensilimab and balstilimab in treatment-refractory hepat
About this update from Agenus Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1694,"height":353,"url":"https://media.zenfs.com/en/business-wire.com/8e31ef6869cda0bc06644852a17b1c89"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AbpZyzsrmS5NiJ7L_jeRvA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIwMA--/https://media.zenfs.com/en/business-wire.com/8e31ef6869cda0bc06644852a17b1c89","width":960,"height":200},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/pBcYRCFI.kK_ktuU_SrxPg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTEzMw--/https://media.zenfs.com/en/business-wire.com/8e31ef6869cda0bc06644852a17b1c89","width":640,"height":133},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/mSdTf2PcSBDSyQE3PBQASQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01MDA-/https://media.zenfs.com/en/business-wire.com/8e31ef6869cda0bc06644852a17b1c89","width":1200,"height":250}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Published prospective cohort showed durable responses and manageable safety in patients with HCC following prior immunotherapy","length":126,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Median overall survival of 12.3 months in a heavily pretreated population with poor prognostic features, including ALBI grade 2 liver function","length":142,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":268,"olType":false},{"type":"text","content":"LEXINGTON, Mass., May 15, 2026--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the publication of Phase 1b data evaluating botensilimab (BOT), an Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, in patients with treatment-refractory hepatocellular carcinoma (HCC) who had progressed following prior immunotherapy. The manuscript, titled "A phase 1b study of botensilimab and balstilimab in treatment-refractory hepatocellular carcinoma," was published in Liver Cancer and is available at DOI: 10.1159/000551630.","length":622,"tagName":"p"},{"type":"text","content":"The publication reports results from an expansion cohort of the Phase 1b C-800-01 study in 19 patients with HCC who had progressed on or after prior immunotherapy. The cohort represents a difficult-to-treat population for which ...